Guardant Health’s comprehensive liquid biopsy test, Guardant360, provides quick and reliable treatment decisions for patients with advanced-stage cancer – ET HealthWorld


Guardant Health’s comprehensive liquid biopsy test, Guardant360, provides quick and reliable treatment decisions for patients with advanced-stage cancer
Treatment on time is crucial for patients with advanced-stage cancer. With just a simple blood draw, Guardant Health’s comprehensive liquid biopsy test called Guardant360® allows oncologists to see the current genomic profile of their patient’s tumour in approximately seven days from sample receipt in the laboratory. Using the comprehensive genomic profiling information in the test results, oncologists can recommend appropriate treatment for their patients sooner. Comprehensive genomic profiling is a next-generation sequencing approach that uses a single assay to assess numerous genes including relevant cancer biomarkers as stated in guidelines for therapy guidance. In July this year, the International Association for the Study of Lung Cancer (IASLC) has recommended the adoption of liquid biopsy for patients with advanced-stage non-small cell lung cancer.1

The Guardant360 liquid biopsy test is done using circulating tumour DNA (ctDNA) which is produced when tumours shed small pieces of their DNA into the bloodstream. Traces of this ctDNA can be detected in the blood using digital sequencing technology. Over 70 clinically relevant genes are examined in the test to identify genomic alterations within a patient’s cancer DNA. This helps oncologists understand which alterations exist in a patient’s cancer without the delays and complications of invasive tissue biopsies. Upon receiving the liquid biopsy test results in approximately one week, oncologists can use this genomic information to match their patients to suitable therapies quickly. With tissue biopsies, oncologists encounter several cases in patients where the quantity of tissue is not sufficient or when the tissue is not feasible and they will have to conduct a repeat invasive biopsy, whereas, in the case of a non-invasive liquid biopsy, this problem is non-existent.
“At Guardant Health AMEA, we are committed to making the Guardant360 test available to as many advanced-stage cancer patients as possible so that they can undergo comprehensive genotyping and have the best opportunity to receive suitable treatment for their cancer quickly. We are currently commercially available in 41 countries across Asia, Middle East and Africa (AMEA) including India,” said Mr Simranjit Singh, Chief Executive Officer of Guardant Health AMEA.

As the world’s first comprehensive liquid biopsy to receive approval from the U.S. Food and Drug Administration (FDA) for comprehensive tumour mutation profiling across all solid cancers in August last year, the Guardant360 test continues to be ordered by leading oncologists in AMEA to help guide treatment decisions for patients with advanced-stage cancer.

“Advanced stage cancer patients who require urgent treatment and may have a high risk for tissue biopsy would benefit from Guardant360. I strongly believe in fast action against growing tumour and Guardant360 has made this possible in my clinic,” said Prof. Byoung Chul Cho, Professor, Division of Medical Oncology from the Yonsei Cancer Centre in Seoul, South Korea.

“The Guardant360 liquid biopsy test was effective in detecting actionable mutations in the solid tumours of my patients with advanced-stage cancer and this helped me to make quick, reliable and effective treatment decisions,” said Dr Amit Rauthan, Medical Oncologist from the Department of Medical Oncology in Manipal Hospital in Bangalore, India.

“In several cases of breast cancer where the disease progresses to the bone, liquid biopsies like Guardant360 become very useful in clinical practice as it’s very difficult to biopsy bone. In such cases, this test gives us the comprehensive genomic information required to treat patients appropriately. It also gives us the ability to track mutations that are acquired over time that may help modify therapeutic strategies,” said Dr Shaheenah Dawood, Consultant Medical Oncologist from Mediclinic City Hospital in Dubai, U.A.E.

Highly validated by over 200 peer-reviewed publications, the Guardant360 liquid biopsy test offered by Guardant Health AMEA has shown high agreement with tissue biopsies in detecting actionable mutations and this has helped to guide treatment decisions for patients with advanced-stage cancer. Guardant Health AMEA hopes to accelerate wider adoption of guideline-recommended genomic profiling in clinical practice among medical oncologists so that patients in AMEA can benefit from reliable, comprehensive liquid biopsies such as Guardant360 and be treated quickly and accurately. For more information on the Guardant360 liquid biopsy test, click here to find out more.

Reference: 1. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC), available here accessed on 30 July 2021.

Disclaimer: The views and opinions expressed in the story are independent professional judgment of the doctors/experts and we do not take any responsibility for the accuracy of their views. This should not be considered as a substitute for medical advice. Please consult your treating physician for more details.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *